Originally spun out of the MIT Department of Chemistry in 2013, C2Sense has developed two distinct product platforms that leverage core technological breakthroughs in chemistry and photography united by the innovative application of fluorescence.
In the diagnostic space, C2Sense’s Halo platform , to provide patients and providers alike with laboratory-level accuracy at low-cost and at the point of need. In the supply chain space, C2Sense creating new product assessment techniques with a growing list of applications including product verification and authentication; moisture, oxygen and temperature sensing; and discrete traceability or visible labeling.
C2Sense is doing amazing work applying technological breakthroughs in chemistry, machine vision, and material science, to provide laboratory-level accuracy at low-cost and at the point of need.
Our Story
Our Team
Headquartered in Watertown, Massachusetts, the Halo team features 14 scientists, engineers, and business leaders designing and implementing innovative solutions with the goal of dependable and accessible diagnostics for all people.
Halo® in the News
April 9, 2024 - C2Sense, Inc., and Princeton BioMeditech Corporation (PBM) announced today that they have secured a second National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech High Performance award.
October 30, 2023 - C2Sense, Inc. has published a paper demonstrating that smartphone-based luminescence imaging can be a promising tool for time-gated measurements.
April 25, 2023 - C2Sense, Inc., today announced that its Board of Directors has appointed Jim Mahoney, MBA, MMA as an independent director effective January 31, 2023.
March 30, 2023 - C2Sense, Inc., announced the appointment of Adam Behrens, Ph.D., to its Board of Directors as an independent director effective January 31, 2023.
March 8, 2023 – C2Sense, Inc., today announced the appointment of the Honorable Andrew Weber to its Board of Directors effective January 31, 2023.
February 1, 2023 - Digital innovation and connected diagnostics can help address global health disparities, but it is essential to ensure health governance advances alongside new technologies.
January 4, 2023 - C2Sense, Inc. announced today the successful second closing of its $8M Series B financing round with participation from new and existing investors.
August 25, 2022 - C2Sense, Inc., is a technology company developing a suite of diagnostic products for healthcare, wellness and safety.
April 18, 2022- C2Sense, Inc. has published a proof-of-concept study in Frontiers in Public Health demonstrating the sensitivity and specificity of its Halo technology platform to detect SARS-CoV-2.